GlassScriptPhysician profile
Omid Rad Pour
NPI 1437367901
$8,577.16
in general payments reported to CMS, 2019-2025
45 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $1,523 · 2021: $930 · 2022: $1,084 · 2023: $978 · 2024: $1,582 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,589.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $827.15 | 2019-2025 | Tepezza, Repatha, Repatha |
| Abbott Laboratories | $567.31 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $490.99 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $473.96 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.45 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $399.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $343.12 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $284.01 | 2025 | |
| Lilly USA, LLC | $282.90 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $279.53 | 2022-2025 | |
| Chiesi USA, INC. | $228.08 | 2024-2025 | Myalept, Mycapssa |
| Insulet Corporation | $227.98 | 2019-2025 | Omnipod |
| Horizon Therapeutics Plc | $191.41 | 2020-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $174.69 | 2021-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Rad Pour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.